FR11C0022I1 - - Google Patents

Info

Publication number
FR11C0022I1
FR11C0022I1 FR11C0022C FR11C0022I1 FR 11C0022 I1 FR11C0022 I1 FR 11C0022I1 FR 11C0022 C FR11C0022 C FR 11C0022C FR 11C0022 I1 FR11C0022 I1 FR 11C0022I1
Authority
FR
France
Prior art keywords
cell
papillomavirus capsid
protein
expression
capsomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26703787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0022(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/028,517 external-priority patent/US8062642B1/en
Publication of FR11C0022I1 publication Critical patent/FR11C0022I1/fr
Application filed filed Critical
Application granted granted Critical
Publication of FR11C0022I2 publication Critical patent/FR11C0022I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
FR11C0022C 1993-03-09 2011-07-04 Production de proteine de capside de virus du papillome humain et particules de type viral Active FR11C0022I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/028,517 US8062642B1 (en) 1993-03-09 1993-03-09 Production of papillomavirus capsid protein and virus-like particles
US20730994A 1994-03-07 1994-03-07
EP94912186A EP0688227B1 (en) 1993-03-09 1994-03-08 Production of human papillomavirus capsid protein and virus-like particles

Publications (2)

Publication Number Publication Date
FR11C0022I1 true FR11C0022I1 (cs) 2011-05-08
FR11C0022I2 FR11C0022I2 (fr) 2012-08-03

Family

ID=26703787

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0022C Active FR11C0022I2 (fr) 1993-03-09 2011-07-04 Production de proteine de capside de virus du papillome humain et particules de type viral

Country Status (13)

Country Link
EP (3) EP1588713B1 (cs)
JP (4) JPH08507685A (cs)
AT (3) ATE296111T1 (cs)
AU (3) AU688759C (cs)
CA (1) CA2157932C (cs)
DE (9) DE122007000089I1 (cs)
DK (2) DK1618888T3 (cs)
ES (3) ES2263406T3 (cs)
FR (1) FR11C0022I2 (cs)
LU (3) LU91313I2 (cs)
NL (3) NL300265I2 (cs)
PT (2) PT688227E (cs)
WO (1) WO1994020137A1 (cs)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233687T2 (de) 1991-07-19 2007-10-18 University Of Queensland, St. Lucia Impfstoff gegen Humanes Papillomavirus (Typ 18)
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
DE4415743C2 (de) * 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AU2003235191B2 (en) * 1994-10-07 2006-09-21 Loyola University Of Chicago Papilloma virus-like particles, fusion proteins as well as processes for their production
DE122007000093I1 (de) * 1994-10-07 2008-03-27 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
WO1996026277A1 (en) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
ES2213185T3 (es) * 1995-11-15 2004-08-16 MERCK & CO., INC. Particulas de tipo virus hpv11 sinteticas.
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
ATE256734T1 (de) * 1996-10-04 2004-01-15 Merck & Co Inc Synthetische hpv16 virus-ähnliche partikel
CA2274474C (en) * 1996-12-09 2008-07-22 Steven Ludmerer Synthetic hpv16 virus-like particles
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
ATE490346T1 (de) * 2000-09-18 2010-12-15 Medimmune Llc In vitro testverfahren zur bestimmung der immunogenizität eines impfstoffes
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
WO2003103570A2 (en) 2001-08-01 2003-12-18 University Of Rochester Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
AU2006236905B2 (en) 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006065166A1 (en) * 2005-07-26 2006-06-22 Obschestvo S Ogranichennoi Otvetstvennostyu 'rusgen' Protein l1 and protein e7 peptide-based composition for treating and preventing a human papillomaviral infection
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2008082719A2 (en) 2006-08-30 2008-07-10 University Of Rochester Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
CA2662921C (en) 2006-09-26 2018-11-20 Infectious Disease Research Institute Vaccine and pharmaceutical compositions and kits and uses thereof in stimulating an immune response with a synthetic glucopyranosyl lipid adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
BRPI0808553A2 (pt) 2007-03-02 2014-08-19 Glaxosmithkline Biolog Sa Métodos para elevar uma resposta imune contra um patógeno, para estimar a produção de células t cd4+ e/ou cd8+ e/ou anticorpos específicos de patógeno em mamíferos e para estimular uma resposta imune em um mamífero, composição de vacina, uso da mesma, e, kit
DK2154147T3 (en) * 2007-04-29 2015-12-07 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated L1 protein of human papillomavirus 16
WO2008134935A1 (en) 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated human papillomavirus type 18 l1 proteins
DK2907821T3 (en) 2007-05-29 2017-04-10 Univ Xiamen Process for Preparation of an N-Terminal Truncated L1 Protein of Human Papillomavirus (HPV)
BRPI0810951B8 (pt) 2007-05-29 2021-05-25 Beijing Wantai Biological Pharmacy Entpr Co Ltd proteína l1 do hpv6, polinucleotídeo, vetor, célula, partícula semelhante ao vírus (vlp) hpv6, método para produzir a proteína hpv6 l1 truncada, vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína hpv6 l1 truncada, método para prevenção de condiloma acuminado ou infecções por hpv, método para obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv
US20110091496A1 (en) * 2008-01-19 2011-04-21 Graham Barney S Methods and compositions for the delivery of vaccines to disrupted epithelium
EP2280728B1 (en) 2008-05-26 2016-03-02 Cadila Healthcare Limited Combined measles-human papilloma vaccine
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
EP2414512A1 (en) * 2009-04-03 2012-02-08 Deutsches Krebsforschungszentrum Enhanced production of papillomavirus-like particles with a modified baculovirus expression system
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
EP3730943B1 (en) 2010-04-08 2025-01-29 University of Pittsburgh - Of the Commonwealth System of Higher Education B-cell antigen presenting cell assay
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
SI2811981T1 (sl) 2012-02-07 2019-08-30 Infectious Disease Research Institute Izboljšanje adjuvantne formulacije, ki obsegajo TLR4 agoniste in postopki za uporabo le-teh
US20150110824A1 (en) 2012-03-18 2015-04-23 Glaxosmithkline Biologicals, Sa Method of vaccination against human papillomavirus
AU2013262691B2 (en) 2012-05-16 2018-12-20 Immune Design Corp. Vaccines for HSV-2
EP3587455A1 (en) 2012-10-23 2020-01-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
CA3010905A1 (en) 2016-02-22 2017-08-31 Boehringer Ingelheim Vetmedica Gmbh Method for the immobilization of biomolecules
IL319503A (en) 2016-05-16 2025-05-01 Access To Advanced Health Inst PEGylated liposomes and methods of use
IL314130A (en) 2016-05-16 2024-09-01 Access To Advanced Health Inst Formulation containing tlr agonist and methods of use
IL315825A (en) 2016-06-01 2024-11-01 Access To Advanced Health Inst Nanoalum particles containing a fixing factor
JP2020524143A (ja) 2017-06-15 2020-08-13 インフェクシャス ディズィーズ リサーチ インスティチュート ナノ構造脂質担体、安定エマルジョン、およびその使用
US20200276299A1 (en) 2017-09-08 2020-09-03 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
US12318436B2 (en) 2019-05-25 2025-06-03 Access To Advanced Health Institute Composition and method for spray drying an adjuvant vaccine emulsion
WO2022051022A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Co-lyophilized rna and nanostructured lipid carrier
EP4291231A1 (en) 2021-02-11 2023-12-20 GlaxoSmithKline Biologicals S.A. Hpv vaccine manufacture
IL319329A (en) 2022-09-09 2025-05-01 Access To Advanced Health Inst Immunogenic vaccine composition incorporating saponin
CN116375816B (zh) * 2023-01-06 2023-09-05 北京康乐卫士生物技术股份有限公司 一种人乳头瘤病毒56型l1蛋白突变体及减少重组蛋白降解的方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956288A (en) * 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
NZ232913A (en) 1989-03-15 1992-08-26 Gist Brocades Nv Il-3 produced recombinantly and purified to homogeneity; vectors and pharmaceutical preparations
DE69233687T2 (de) * 1991-07-19 2007-10-18 University Of Queensland, St. Lucia Impfstoff gegen Humanes Papillomavirus (Typ 18)

Also Published As

Publication number Publication date
AU2007201005B2 (en) 2010-06-10
HK1082206A1 (en) 2006-06-02
LU91392I2 (fr) 2008-02-14
DE05075889T1 (de) 2006-10-05
NL300265I1 (nl) 2007-05-01
JP2010099091A (ja) 2010-05-06
ES2263406T3 (es) 2011-06-06
DE69435332D1 (de) 2011-02-17
CA2157932C (en) 2011-10-11
DE122007000014I1 (de) 2007-05-24
NL300310I1 (nl) 2008-02-01
EP1618888A1 (en) 2006-01-25
EP0688227A1 (en) 1995-12-27
AU688759B2 (en) 1998-03-19
DE122007000090I1 (de) 2008-03-27
EP0688227A4 (en) 1996-05-29
EP0688227B1 (en) 2005-05-25
ES2263406T1 (es) 2006-12-16
LU91391I2 (fr) 2008-02-14
JP2007075117A (ja) 2007-03-29
DE05075369T1 (de) 2006-11-16
DK1618888T3 (da) 2011-04-04
AU688759C (en) 2006-12-21
AU2007201006B2 (en) 2010-07-01
NL300309I2 (nl) 2008-03-03
EP1618888B1 (en) 2011-01-05
EP1588713A1 (en) 2005-10-26
WO1994020137A1 (en) 1994-09-15
ES2263405T3 (es) 2011-04-20
FR11C0022I2 (fr) 2012-08-03
LU91313I2 (fr) 2007-04-23
HK1082196A1 (en) 2006-06-02
JP5306251B2 (ja) 2013-10-02
PT688227E (pt) 2005-10-31
NL300265I2 (nl) 2008-05-01
ATE296111T1 (de) 2005-06-15
DE69434383D1 (de) 2005-06-30
EP1588713B1 (en) 2010-12-22
ES2242955T3 (es) 2005-11-16
JP5386392B2 (ja) 2014-01-15
DE69434383T2 (de) 2005-11-24
DE122007000089I1 (de) 2008-03-27
NL300309I1 (nl) 2008-02-01
AU2007201006A1 (en) 2007-03-29
CA2157932A1 (en) 1994-09-15
JPH08507685A (ja) 1996-08-20
DK0688227T3 (da) 2005-06-27
JP4486075B2 (ja) 2010-06-23
AU6443694A (en) 1994-09-26
ATE492289T1 (de) 2011-01-15
ATE494005T1 (de) 2011-01-15
DE69435331D1 (de) 2011-02-03
JP2010148514A (ja) 2010-07-08
ES2242955T4 (es) 2010-04-12
DE122011100018I1 (de) 2011-11-17
PT1618888E (pt) 2011-04-08
ES2263405T1 (es) 2006-12-16
AU2007201005A1 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
FR11C0022I1 (cs)
NL300323I1 (nl) Op papillomavirus lijkende deeltjes, fusie-eiwitten alsook werkwijze
PL317234A1 (en) Vaccines against papilloma virus
EA199700281A1 (ru) Молекула днк, кодирующая белок l1 вируса папилломы типа 11 чепловека, экспрессирующий вектор, способ получения очищенных вирусоподобных частиц
WO1997004099A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
DK0750669T3 (da) Modificeret papillomavirus-L2-protein og VLP'er dannet derudfra
AU7649996A (en) Fused DNA sequence, fused protein expressed from said fused DNA sequence and method for expressing said protein
ATE290093T1 (de) EXPRIMIERUNG EINES MODIFIZIERTEM ßFOAMY VIRUS ENVELOPE PROTEINß (HÜLLENPROTEIN)
WO2002026943A3 (fr) Production de particules pseudovirales de vhc en cellules d'insectes
WO2000047722A3 (de) Chimäre virus-ähnliche partikel bzw. chimäre capsomere von bpv (bovine papilloma virus)